Wai Meng David Tai

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri et al. · The Lancet · 2025 · 151 citations · Full text

Hepatology, Transarterial Chemoembolisation, Medicine +8

Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

Robin Kate Kelley, Bruno Sangro, William Proctor Harris et al. · Journal of Clinical Oncology · 2020 · 102 citations

Immunology, Immunoediting, Pathology +25

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)

Wai Meng David Tai, Wei Peng Yong, Cindy Lim et al. · Annals of Oncology · 2016 · 61 citations · Full text

Phase Ib Study, Hepatology, Medicine +7

Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in <i>BRAF</i> V600-dependent advanced solid tumors.

Richard Kefford, Wilson H. Miller, Daniel Shao-Weng Tan et al. · Journal of Clinical Oncology · 2013 · 43 citations

Dose-escalation Study, Tumor Biology, Phase Ib/ii +14

Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach et al. · Cancer Research · 2019 · 43 citations

I/ii Study, Medicine, Pharmacology +14